MacDonald I M, Noel L P, Mintsioulis G, Clarke W N
Department of Biochemistry, University of Ottawa, Ontario, Canada.
J Pediatr Ophthalmol Strabismus. 1990 Sep-Oct;27(5):272-4. doi: 10.3928/0191-3913-19900901-14.
We studied the usefulness of topical cysteamine ophthalmic drops in reducing crystal formation within the corneas of patients affected by nephropathic cystinosis. A dosage of 0.3% cysteamine given four times daily was chosen as a more manageable method than a previously reported protocol of hourly administration of 0.11% drops. No reduction in crystal formation was observed in our patients; they were followed for seven months.
我们研究了外用半胱胺眼药水在减少患有肾病性胱氨酸病患者角膜内晶体形成方面的有效性。与之前报道的每小时滴注0.11%眼药水的方案相比,选择每日四次给予0.3%半胱胺的给药剂量作为一种更易于管理的方法。在我们的患者中未观察到晶体形成减少;他们被随访了七个月。